Beximco Pharmaceuticals PLC. (DSE:BXPHARMA)
Bangladesh · Delayed Price · Currency is BDT 150.00
-0.60 (-0.40%)
At close: Jul 6, 2026
DSE:BXPHARMA Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 53,926 | 49,120 | 44,392 | 39,267 | 34,669 | 29,494 | |
Revenue Growth (YoY) | 12.43% | 10.65% | 13.05% | 13.26% | 17.55% | 15.16% |
Cost of Revenue | 28,357 | 27,071 | 24,989 | 22,164 | 18,989 | 15,677 |
Gross Profit | 25,569 | 22,049 | 19,403 | 17,102 | 15,681 | 13,816 |
Selling, General & Admin | 14,237 | 12,662 | 11,112 | 10,200 | 9,101 | 7,470 |
Operating Expenses | 14,237 | 12,662 | 11,112 | 10,200 | 9,101 | 7,470 |
Operating Income | 11,332 | 9,387 | 8,291 | 6,902 | 6,580 | 6,346 |
Interest Expense | -681.08 | -964.08 | -1,121 | -1,242 | -925.6 | -805.87 |
Interest & Investment Income | 177.04 | 80.71 | 17.08 | 7.46 | 5.07 | 3.32 |
Currency Exchange Gain (Loss) | -40.9 | 5.73 | 8.9 | 66.94 | 50.12 | -3.72 |
Other Non Operating Income (Expenses) | 483.56 | 457.28 | 311.17 | 314.3 | 402.75 | 298.91 |
EBT Excluding Unusual Items | 11,271 | 8,966 | 7,507 | 6,049 | 6,112 | 5,839 |
Merger & Restructuring Charges | - | - | - | - | -57.3 | -18.21 |
Gain (Loss) on Sale of Assets | 43.37 | 34.93 | 16.38 | 13.82 | 12.62 | 3.96 |
Other Unusual Items | 2.73 | 2.73 | 2.4 | 6.1 | 619.47 | 552.99 |
Pretax Income | 11,317 | 9,004 | 7,525 | 6,069 | 6,687 | 6,378 |
Income Tax Expense | 2,530 | 2,005 | 1,659 | 1,544 | 1,688 | 1,212 |
Earnings From Continuing Operations | 8,786 | 6,999 | 5,867 | 4,524 | 4,999 | 5,166 |
Minority Interest in Earnings | -136.93 | -58.25 | -37.24 | 89.6 | 124.51 | -38.06 |
Net Income | 8,650 | 6,941 | 5,830 | 4,614 | 5,123 | 5,128 |
Net Income to Common | 8,650 | 6,941 | 5,830 | 4,614 | 5,123 | 5,128 |
Net Income Growth | 28.90% | 19.06% | 26.34% | -9.94% | -0.09% | 45.89% |
Shares Outstanding (Basic) | 446 | 446 | 446 | 446 | 446 | 446 |
Shares Outstanding (Diluted) | 446 | 446 | 446 | 446 | 446 | 446 |
EPS (Basic) | 19.39 | 15.56 | 13.07 | 10.34 | 11.48 | 11.49 |
EPS (Diluted) | 19.39 | 15.56 | 13.07 | 10.34 | 11.48 | 11.49 |
EPS Growth | 28.90% | 19.06% | 26.34% | -9.94% | -0.09% | 45.89% |
Free Cash Flow | 7,242 | 4,441 | 6,371 | 3,674 | 2,399 | 3,503 |
Free Cash Flow Per Share | 16.23 | 9.96 | 14.28 | 8.24 | 5.38 | 7.85 |
Dividend Per Share | 4.750 | 4.750 | 4.000 | 3.500 | 3.500 | 3.500 |
Dividend Growth | 18.75% | 18.75% | 14.29% | - | - | 156.67% |
Gross Margin | 47.42% | 44.89% | 43.71% | 43.55% | 45.23% | 46.84% |
Operating Margin | 21.01% | 19.11% | 18.68% | 17.58% | 18.98% | 21.52% |
Profit Margin | 16.04% | 14.13% | 13.13% | 11.75% | 14.78% | 17.39% |
Free Cash Flow Margin | 13.43% | 9.04% | 14.35% | 9.36% | 6.92% | 11.88% |
EBITDA | 13,109 | 11,089 | 10,284 | 8,962 | 8,247 | 7,460 |
EBITDA Margin | 24.31% | 22.57% | 23.17% | 22.82% | 23.79% | 25.30% |
D&A For EBITDA | 1,777 | 1,702 | 1,994 | 2,061 | 1,667 | 1,114 |
EBIT | 11,332 | 9,387 | 8,291 | 6,902 | 6,580 | 6,346 |
EBIT Margin | 21.01% | 19.11% | 18.68% | 17.58% | 18.98% | 21.52% |
Effective Tax Rate | 22.36% | 22.27% | 22.04% | 25.45% | 25.25% | 19.00% |
Advertising Expenses | - | 273.21 | 241.76 | 212.23 | 196.72 | 160 |